Opinion|Videos|July 16, 2024
Economic Impacts and Pricing Strategies Surrounding Biosimilars
The panel discusses the economic impact biosimilars have across different patient types.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What economic impacts do biosimilars have in different delivery channels (inpatient, self-administered outpatient, outpatient infusion)?
- How do pricing strategies for biosimilars, such as the high and low list prices of adalimumab biosimilars, affect their market penetration and adoption?
- How do biosimilar pricing strategies affect patient access and affordability?
- Are there more effective pricing models that could be adopted?
- Are there certain customer subtypes that will want a rebate drive model vs. those want a rebate driven model vs. a WAC driven model?
Advertisement
Related to this article
From 9.6 million US diabetic retinopathy cases to a new FDA warning on GLP-1s, here are 5 things to know about diabetic eye disease this November.
The action is based on phase 3 VOLGA results, which were presented at the ESMO Congress 2026. They support a perioperative regimen that limits the antibody-drug conjugate to 3 cycles before bladder removal.
New CMS data let EBRI measure what employer plans owe after No Surprises Act arbitration: $8.39B in 2025, though premium impact is unclear.
In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.
Kirsten Axelsen, MS, discusses gaps in biomarker testing, nonmedical barriers, and utilization management from a new report on access to CLL care.
A new meta-analysis finds pulmonary rehabilitation and other nonpharmacological interventions ease lung cancer cough, dyspnea, and improve QOL.
Machine learning models for upper extremity soft tissue sarcoma had a C-index of 0.79 for local recurrence, similar to nomograms, in a 188-patient cohort.
Protein intake below 0.6 g/kg/d was linked to a higher risk of kidney failure and death, according to a Korean cohort study.
Advertisement
Advertisement
Trending on AJMC
1
Real-World Cohort Ties JAK Inhibitors in Alopecia Areata to Menstrual Side Effects
2
Phase 3 Trial Tests Ensifentrine for COPD Exacerbation Prevention
3
Trends in Pharmacy Benefit Manager Market Dynamics, 2016-2025
4
Tarlatamab Plus Durvalumab Cuts Risk of Death by 58% as First-Line Maintenance in ES-SCLC
5